Neurological and Psychiatric Disorders

Drug candidates with innovative neuroscience mechanisms at the cutting edge of science

Pipeline

Targeting Conditions Where Current Treatments Fail to Address Unmet Medical Needs

We have a portfolio of clinical and preclinical compounds that we believe are best-in-class due to their unique mechanism of action and where human proof of concept has been established for the compound or the target.

Candidate Mechanism Indications Preclinical Phase 1 Phase 2 Phase 3
CERC-501 Selective kappa opioid receptor (KOR) antagonist Adjunctive treatment of MDD Planned Study
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
CERC-501 Selective kappa opioid receptor (KOR) antagonist Smoking Relapse Collaboration
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
CERC-501 Selective kappa opioid receptor (KOR) antagonist Mood and Anxiety External Study
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
CERC-501 Selective kappa opioid receptor (KOR) antagonist Cocaine Addiction External Study
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
CERC-501 Selective kappa opioid receptor (KOR) antagonist PTSD External Study
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
CERC-3011 NR2B specific NMDA antagonist Adjunctive treatment of MDD with a rapid onset
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress

1

Phase 3 Phase not started
CERC-611 AMPA-TARP-γ8 antagonist Adjunctive treatment of partial-onset seizures in epilepsy
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
CERC-406 Selective, brain penetrant COMT inhibitor Residual cognitive impairment symptoms of MDD
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
  1. Top-line results reported in November 2016; planned next steps will be announced at a later time.
Market Need: Addressing the Continued CNS Burden

Market Need: Addressing the Continued CNS Burden

Central nervous system (CNS) disorders are associated with the highest medical treatment and long-term care costs and overall economic burden.

Scientific Publications

Patient Resources

Learn more about the CNS disorders we’re targeting, as well as contact information for help hotlines.

View Patient Resources